Anwer F - Search Results

1

Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.

Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, Oliver-Caldés A, Stölzel F, Rathje K, Fischer L, Born P, Schäfer L, Albici AM, Schub N, Kfir-Erenfeld S, Assayag M, Asherie N, Wulf GG, Kharboutli S, Müller F, Shune L, Davis JA, Anwer F, Vucinic V, Platzbecker U, Ayuk F, Kröger N, Khouri J, Gurnari C, McGuirk J, Stepensky P, Abdallah AO, Fernández de Larrea C. Gagelmann N, et al. Among authors: anwer f. J Clin Oncol. 2024 May 10;42(14):1665-1675. doi: 10.1200/JCO.23.02232. Epub 2024 Feb 15. J Clin Oncol. 2024. PMID: 38358946

2

Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis.

Mian A, Wei W, Winter AM, Khouri J, Jagadeesh D, Anwer F, Gerds AT, Dean RM, Sobecks R, Pohlman B, Hamilton BK, Majhail NS, Hill BT. Mian A, et al. Among authors: anwer f. Leuk Lymphoma. 2021 Jun;62(6):1344-1352. doi: 10.1080/10428194.2020.1864349. Epub 2020 Dec 29. Leuk Lymphoma. 2021. PMID: 33375873

3

Carfilzomib-Based 3-Drug Regimens for Newly Diagnosed Multiple Myeloma-All That Glitters Is Not Gold.

Hashmi H, Shah Z, Anwer F. Hashmi H, et al. Among authors: anwer f. JAMA Oncol. 2021 Jul 1;7(7):967-968. doi: 10.1001/jamaoncol.2021.0174. JAMA Oncol. 2021. PMID: 33792618 No abstract available.

4

Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis.

Latif A, Kapoor V, Lateef N, Ahsan MJ, Usman RM, Malik SU, Ahmad N, Rosko N, Rudoni J, William P, Khouri J, Anwer F. Latif A, et al. Among authors: anwer f. Cardiovasc Hematol Disord Drug Targets. 2021;21(1):30-45. doi: 10.2174/1871529X21666210412113017. Cardiovasc Hematol Disord Drug Targets. 2021. PMID: 33845729

5

Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study.

Covut F, Ahmed R, Chawla S, Ricaurte F, Samaras CJ, Anwer F, Garcia AVM, Angelini DE, Mazzoni S, Faiman B, Valent J, Khouri J. Covut F, et al. Among authors: anwer f. Br J Haematol. 2021 Jun;193(6):1213-1219. doi: 10.1111/bjh.17505. Epub 2021 May 17. Br J Haematol. 2021. PMID: 33997961 Clinical Trial.

6

Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019.

Balmaceda N, Aziz M, Chandrasekar VT, McClune B, Kambhampati S, Shune L, Abdallah AO, Anwer F, Majeed A, Qazilbash M, Ganguly S, McGuirk J, Mohyuddin GR. Balmaceda N, et al. Among authors: anwer f. BMC Cancer. 2021 Jun 26;21(1):730. doi: 10.1186/s12885-021-08451-x. BMC Cancer. 2021. PMID: 34172037 Free PMC article.

7

Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy.

Chakraborty R, Rybicki L, Valent J, Garcia AVM, Faiman BM, Khouri J, Samaras CJ, Anwer F, Khorana AA. Chakraborty R, et al. Among authors: anwer f. Blood Cancer J. 2021 Jun 25;11(6):121. doi: 10.1038/s41408-021-00513-4. Blood Cancer J. 2021. PMID: 34172719 Free PMC article. No abstract available.

8

Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review.

George LL, Deshpande SR, Cortese MJ, Kendall EK, Chattaraj A, Shah Z, Zhao J, Anwer F. George LL, et al. Among authors: anwer f. Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):741-751. doi: 10.1016/j.clml.2021.06.003. Epub 2021 Jun 15. Clin Lymphoma Myeloma Leuk. 2021. PMID: 34253497

9

Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.

Khattak ZE, Hashmi H, Khan SI, Aamir S, Arif U, Khan AI, Darwin A, Singh AD, Khouri J, Anwer F. Khattak ZE, et al. Among authors: anwer f. Ann Hematol. 2021 Sep;100(9):2155-2172. doi: 10.1007/s00277-021-04599-5. Epub 2021 Jul 27. Ann Hematol. 2021. PMID: 34318356

10

Progress in research: Daratumumab improves treatment outcomes of patients with AL amyloidosis.

Hassan H, Anwer F, Javaid A, Hashmi H. Hassan H, et al. Among authors: anwer f. Crit Rev Oncol Hematol. 2021 Sep;165:103435. doi: 10.1016/j.critrevonc.2021.103435. Epub 2021 Jul 31. Crit Rev Oncol Hematol. 2021. PMID: 34343658 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

212 results

Search Page